SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for EVAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 4.527M
March 31, 2026 3.018M
December 31, 2025 1.491M
September 30, 2025 1.878M
June 30, 2025 4.018M
March 31, 2025 6.00M
December 31, 2024 7.607M
September 30, 2024 7.886M
June 30, 2024 8.662M
March 31, 2024 9.418M
December 31, 2023 10.36M
September 30, 2023 10.68M
June 30, 2023 9.768M
March 31, 2023 9.163M
Date Value
December 31, 2022 8.201M
September 30, 2022 7.292M
June 30, 2022 6.777M
March 31, 2022 6.557M
December 31, 2021 6.244M
September 30, 2021 6.476M
June 30, 2021 6.730M
March 31, 2021 6.201M
December 31, 2020 4.922M
September 30, 2020 3.909M
June 30, 2020 2.165M
March 31, 2020 0.7815M
December 31, 2019 0.7815M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Autolus Therapeutics Plc 152.92M
Cellectis SA 21.32M
DBV Technologies SA 56.62M
Ascendis Pharma A/S 662.10M
Akari Therapeutics Plc 8.796M